Showing results for "Ocular"
business
Novartis Staying Conscious of Cost in Challenging Deal MarketSwiss drugmaker Novartis AG has said it expects to bring a series of potential blockbuster treatments to market over the next few years, but like many of its fellow pharmaceutical giants, it is under persistent pressure to restock its pipeline.January 10, 2022
business
Looking Back at a Crazy 2021 for SPACs and IPOsHi, it’s IPO reporter Crystal Tse here. Today in our Bloomberg Deals newsletter, we’re looking back at a wild year for SPACs and IPOs, as well as Triller’s merger with Seachange and an Australian data services deal. Today's top storiesDecember 22, 2021
business
Novartis to Buy Ocular Gene Therapy Firm for Up to $1.5 BillionNovartis AG agreed to buy Gyroscope Therapeutics, a U.K.-based ocular gene therapy company, for as much as $1.5 billion as the pharmaceutical giant pursues acquisitions of smaller firms with promising drug pipelines.December 22, 2021